Literature DB >> 20717103

Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.

Martin A Hausl1, Wenli Zhang, Nadine Müther, Christina Rauschhuber, Helen G Franck, Elizabeth P Merricks, Timothy C Nichols, Mark A Kay, Anja Ehrhardt.   

Abstract

Sleeping Beauty (SB) transposase enables somatic integration of exogenous DNA in mammalian cells, but potency as a gene transfer vector especially in large mammals has been lacking. Herein, we show that hyperactive transposase system delivered by high-capacity adenoviral vectors (HC-AdVs) can result in somatic integration of a canine factor IX (cFIX) expression-cassette in canine liver, facilitating stabilized transgene expression and persistent haemostatic correction of canine hemophilia B with negligible toxicity. We observed stabilized cFIX expression levels during rapid cell cycling in mice and phenotypic correction of the bleeding diathesis in hemophilia B dogs for up to 960 days. In contrast, systemic administration of an inactive transposase system resulted in rapid loss of transgene expression and transient phenotypic correction. Notably, in dogs a higher viral dose of the active SB transposase system resulted into transient phenotypic correction accompanied by transient increase of liver enzymes. Molecular analysis of liver samples revealed SB-mediated integration and provide evidence that transgene expression was derived mainly from integrated vector forms. Demonstrating that a viral vector system can deliver clinically relevant levels of a therapeutic protein in a large animal model of human disease paves a new path toward the possible cure of genetic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717103      PMCID: PMC2990515          DOI: 10.1038/mt.2010.169

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Improved system for helper-dependent adenoviral vector production.

Authors:  Donna Palmer; Philip Ng
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

2.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.

Authors:  M A Kay; S Rothenberg; C N Landen; D A Bellinger; F Leland; C Toman; M Finegold; A R Thompson; M S Read; K M Brinkhous
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

4.  Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.

Authors:  Daniel A Muruve; Matthew J Cotter; Anne K Zaiss; Lindsay R White; Qiang Liu; Trevor Chan; Sharon A Clark; P Joel Ross; Robert A Meulenbroek; Gunhild M Maelandsmo; Robin J Parks
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

6.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

7.  In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Authors:  M A Kay; C N Landen; S R Rothenberg; L A Taylor; F Leland; S Wiehle; B Fang; D Bellinger; M Finegold; A R Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

8.  Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; Z Xiang; H C Ertl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

9.  Canine hemophilia B resulting from a point mutation with unusual consequences.

Authors:  J P Evans; K M Brinkhous; G D Brayer; H M Reisner; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B.

Authors:  Nicola Brunetti-Pierri; Nathan C Grove; Yu Zuo; Rachel Edwards; Donna Palmer; Vincenzo Cerullo; Jun Teruya; Philip Ng
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

View more
  38 in total

1.  Mobilization of DNA transposable elements from lentiviral vectors.

Authors:  Rasmus O Bak; Jacob Giehm Mikkelsen
Journal:  Mob Genet Elements       Date:  2011-07-01

Review 2.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

Review 3.  The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

Authors:  Elena L Aronovich; R Scott McIvor; Perry B Hackett
Journal:  Hum Mol Genet       Date:  2011-04-01       Impact factor: 6.150

Review 4.  State-of-the-art gene-based therapies: the road ahead.

Authors:  Mark A Kay
Journal:  Nat Rev Genet       Date:  2011-04-06       Impact factor: 53.242

5.  Standard free droplet digital polymerase chain reaction as a new tool for the quality control of high-capacity adenoviral vectors in small-scale preparations.

Authors:  Philip Boehme; Thorsten Stellberger; Manish Solanki; Wenli Zhang; Eric Schulz; Thorsten Bergmann; Jing Liu; Johannes Doerner; Armin E Baiker; Anja Ehrhardt
Journal:  Hum Gene Ther Methods       Date:  2015-02       Impact factor: 2.396

Review 6.  Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Virus Genes       Date:  2017-06-07       Impact factor: 2.332

Review 7.  In Vivo Hematopoietic Stem Cell Transduction.

Authors:  Maximilian Richter; Daniel Stone; Carol Miao; Olivier Humbert; Hans-Peter Kiem; Thalia Papayannopoulou; André Lieber
Journal:  Hematol Oncol Clin North Am       Date:  2017-10       Impact factor: 3.722

8.  Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Authors:  Elena L Aronovich; Kendra A Hyland; Bryan C Hall; Jason B Bell; Erik R Olson; Myra Urness Rusten; David W Hunter; N Matthew Ellinwood; R Scott McIvor; Perry B Hackett
Journal:  Hum Gene Ther       Date:  2017-05-19       Impact factor: 5.695

9.  Gene therapy: the promise of a permanent cure.

Authors:  Christopher D Porada; Christopher Stem; Graca Almeida-Porada
Journal:  N C Med J       Date:  2013 Nov-Dec

10.  Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection.

Authors:  Eric K Hubner; Christian Lechler; Thomas N Rösner; Birgit Kohnke-Ertel; Roland M Schmid; Ursula Ehmer
Journal:  J Vis Exp       Date:  2018-02-02       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.